Insight

Drew Moghanaki: CW pain is rare, and when it occurs always heals

Drew Moghanaki/X

May 1, 2025, 16:36

Drew Moghanaki: CW pain is rare, and when it occurs always heals

Drew Moghanaki, Chief Medical Officer at Respirati, shared on X a recent paper by Daniel Raymond et al. published in The Journal of Thoracic and Cardiovascular Surgery:

“While radiation oncologists and medical physicists perseverate about the chest wall V30 and 2% risk of pain after lung SBRT, thoracic surgeons are completing randomized clinical trials of lidocaine and bupivacaine with epinephrine (standard of care) vs cryoanalgesia to address the 100% risk of pain that occurs after lung resection.

My approach is to set a CW limit of 105% of the Rx, and make sure the PTV is fully covered otherwise. CW pain is rare, and when it occurs always heals.”

Title: A randomized study of cryoablation of intercostal nerves in patients undergoing minimally invasive thoracic surgery

Authors: Benny Weksler, Conor Maxwell, Lauren Drake, Lawrence Crist, Kara Specht, Pamela Kuchta, Kurt DeHaven, Isabella Weksler, Brent A. Williams, Hiran C. Fernando

You Can Read the Full Article in JTCVS.

Drew Moghanaki

Other posts featuring Drew Moghanaki on OncoDaily.

Benny Weksler Brent A. Williams cancer Conor Maxwell Drew Moghanaki Hiran C. Fernando Isabella Weksler JTCVS Kara Specht Kurt DeHaven Lauren Drake Lawrence Crist OncoDaily Oncology Pamela Kuchta Respirati SBRT

USA vs Europe: Who Does Cancer Screening Better?

A Call for Peace from the Frontlines of Pediatric Oncology by the POEM Group

Servier Acquires Precision Therapy for Acute Leukemias from BioNova Pharmaceuticals

Penn Medicine: Cancer Center Near Me

Elevating Childhood Cancer and Catastrophic Diseases in the Global NCD Agenda: Joint Call to Action